WO2009050291A3 - Solid dispersion product of n-aryl urea-based drugs - Google Patents

Solid dispersion product of n-aryl urea-based drugs Download PDF

Info

Publication number
WO2009050291A3
WO2009050291A3 PCT/EP2008/064076 EP2008064076W WO2009050291A3 WO 2009050291 A3 WO2009050291 A3 WO 2009050291A3 EP 2008064076 W EP2008064076 W EP 2008064076W WO 2009050291 A3 WO2009050291 A3 WO 2009050291A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid dispersion
dispersion product
aryl urea
based drugs
solvent
Prior art date
Application number
PCT/EP2008/064076
Other languages
French (fr)
Other versions
WO2009050291A2 (en
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Priority to MX2010004291A priority Critical patent/MX2010004291A/en
Priority to EP08839333A priority patent/EP2197425A2/en
Priority to CN200880112150A priority patent/CN101827584A/en
Priority to UAA201006029A priority patent/UA100865C2/en
Priority to AU2008313622A priority patent/AU2008313622A1/en
Priority to CA2699301A priority patent/CA2699301A1/en
Priority to JP2010529408A priority patent/JP2011500649A/en
Priority to BRPI0818340 priority patent/BRPI0818340A2/en
Publication of WO2009050291A2 publication Critical patent/WO2009050291A2/en
Priority to ZA2010/02095A priority patent/ZA201002095B/en
Publication of WO2009050291A3 publication Critical patent/WO2009050291A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A solid dispersion product comprising at least one N-aryl urea-based pharmaceutically active agent is obtained by a) preparing a liquid mixture containing the at least one active agent, at least one pharmaceutically acceptable matrix-forming agent, at least one pharmaceutically acceptable surfactant and at least one solvent, and b) removing the solvent(s) from the liquid mixture to obtain the solid dispersion product.
PCT/EP2008/064076 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs WO2009050291A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2010004291A MX2010004291A (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs.
EP08839333A EP2197425A2 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs
CN200880112150A CN101827584A (en) 2007-10-19 2008-10-17 Solid dispersion product of N-aryl urea-based drugs
UAA201006029A UA100865C2 (en) 2007-10-19 2008-10-17 Normal;heading 1;heading 2;heading 3;SOLID DISPERSION PRODUCT OF N-ARYL UREA-BASED DRUGS
AU2008313622A AU2008313622A1 (en) 2007-10-19 2008-10-17 Solid dispersion product of N-aryl urea-based drugs
CA2699301A CA2699301A1 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs
JP2010529408A JP2011500649A (en) 2007-10-19 2008-10-17 Solid dispersion products of N-arylureas
BRPI0818340 BRPI0818340A2 (en) 2007-10-19 2008-10-17 N-Aryl Urea-based solid drug dispersion product
ZA2010/02095A ZA201002095B (en) 2007-10-19 2010-03-24 Solid dispersion product of n-aryl urea-based drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
US60/999,618 2007-10-19

Publications (2)

Publication Number Publication Date
WO2009050291A2 WO2009050291A2 (en) 2009-04-23
WO2009050291A3 true WO2009050291A3 (en) 2010-04-08

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/064076 WO2009050291A2 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs

Country Status (18)

Country Link
EP (1) EP2197425A2 (en)
JP (1) JP2011500649A (en)
KR (1) KR20100087170A (en)
CN (1) CN101827584A (en)
AU (1) AU2008313622A1 (en)
BR (1) BRPI0818340A2 (en)
CA (1) CA2699301A1 (en)
CO (1) CO6270206A2 (en)
CR (1) CR11442A (en)
DO (1) DOP2010000117A (en)
EC (1) ECSP10010183A (en)
GT (1) GT201000102A (en)
MX (1) MX2010004291A (en)
PA (1) PA8800101A1 (en)
RU (1) RU2010119929A (en)
UA (1) UA100865C2 (en)
WO (1) WO2009050291A2 (en)
ZA (1) ZA201002095B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
SG186248A1 (en) * 2010-06-09 2013-01-30 Abbvie Inc Solid dispersions containing kinase inhibitors
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
PL2782557T3 (en) 2011-11-23 2019-03-29 Array Biopharma, Inc. Pharmaceutical formulations
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050574A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050574A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORD J L: "THE CURRENT STATUS OF SOLID DISPERSIONS", PHARMACEUTICA ACTA HELVETIAE, ELSEVIER BV, NETHERLANDS, vol. 61, no. 3, 1 January 1986 (1986-01-01), pages 1 - 20, XP002942684, ISSN: 0031-6865 *
SERAJUDDIN ET AL: "SOLID DISPERSION OF POORLY WATER-SOUBLE DRUGS: EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 88, no. 10, 1 October 1999 (1999-10-01), pages 1058 - 1066, XP000851882, ISSN: 0022-3549 *
YANO K ET AL: "CONSTITUTION OF COLLOIDAL PARTICLES FORMED FROM A SOLID DISPERSION SYSTEM", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 45, no. 8, 1 August 1997 (1997-08-01), pages 1339 - 1344, XP000699691, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
KR20100087170A (en) 2010-08-03
ZA201002095B (en) 2011-11-30
RU2010119929A (en) 2011-11-27
PA8800101A1 (en) 2009-05-15
DOP2010000117A (en) 2010-05-15
WO2009050291A2 (en) 2009-04-23
AU2008313622A1 (en) 2009-04-23
ECSP10010183A (en) 2010-06-29
GT201000102A (en) 2012-03-12
CA2699301A1 (en) 2009-04-23
CO6270206A2 (en) 2011-04-20
JP2011500649A (en) 2011-01-06
MX2010004291A (en) 2010-08-02
BRPI0818340A2 (en) 2015-04-22
UA100865C2 (en) 2013-02-11
CR11442A (en) 2010-09-06
CN101827584A (en) 2010-09-08
EP2197425A2 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
WO2009050289A3 (en) Solid dispersion product containing n-aryl urea-based compound
WO2009050291A3 (en) Solid dispersion product of n-aryl urea-based drugs
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2006089674A3 (en) Tablets with improved drug substance dispersibility
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2008011154A3 (en) Formulations for benzimidazolyl pyridyl ethers
WO2010041141A3 (en) Oil-based foamable carriers and formulations
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
WO2010021607A3 (en) Pharmaceutical formulation
WO2007095342A3 (en) Stable corticosteroid mixtures
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
WO2010017433A3 (en) Use of sucralose as a granulating agent
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2009060952A1 (en) Novel preparation
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2010020799A3 (en) Compositions for the treatment of neoplastic diseases
WO2007086911A3 (en) Stable nanoparticle formulations
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
WO2012029076A3 (en) Stable pharmaceutical composition
WO2010058104A3 (en) Pharmaceutical compositions containing inulin as granulation carrier
WO2008129607A1 (en) Hyaluronan production accelerator and hyaluronan decomposition suppressant
WO2008063284A3 (en) Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
TH104743B (en) Solid diffusion product containing N-aryl urea compounds.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880112150.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08839333

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 583702

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008313622

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2699301

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 204446

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1787/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008839333

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008313622

Country of ref document: AU

Date of ref document: 20081017

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12010500828

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010529408

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004291

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10049271

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20107010979

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201006029

Country of ref document: UA

Ref document number: 2010119929

Country of ref document: RU

Ref document number: 201011442

Country of ref document: CR

Ref document number: CR2010-011442

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: PI 2010001651

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0818340

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100415